Vertex Pharmaceuticals Shares Gain After FDA Approves Non …

Shares of Vertex Pharmaceuticals VRTX 5.31% increase; green up pointing triangle rose after Journavx, the company’s oral non-opioid pain medication, received Food and Drug …

CouponFollow Extension

31%
OFF

Vertex Pharmaceuticals Shares Gain After FDA Approves Non …

2 weeks from now

Shares of Vertex Pharmaceuticals VRTX 5.31% increase; green up pointing triangle rose after Journavx, the company’s oral non-opioid pain medication, received Food and Drug …

wsj.com

8%
OFF

Vertex Pharmaceuticals (VRTX) Set For Painless Gains After FDA …

2 weeks from now

5 days ago · Vertex Pharmaceuticals shares surged 8% in post-market trading on January 30 after securing FDA approval for Journavx, also known as suzetrigine. The drug is the …

businessinsider.com

6%
OFF

Vertex Stock Jumps After Non-Opioid Painkiller Gets FDA Approval

2 weeks from now

Jan 31, 2025 · Vertex will charge $15.50 a pill for Journavx, or $217 for a week’s prescription. (/Associated Press) Shares of Vertex Pharmaceuticals gained about 6% Friday morning, after …

wsj.com

62%
OFF

Vertex Pharmaceuticals Stock Rises As FDA Approves Its Pain Pill

2 weeks from now

Jan 31, 2025 · Vertex Pharmaceuticals (VRTX +0.62%) stock rose on Friday after the Food and Drug Administration (FDA) approved its new painkiller, the first of its kind approved by regulators.

qz.com

6%
OFF

Vertex Stock Jumps After Non-Opioid Painkiller Gets FDA …

2 weeks from now

Jan 31, 2025 · Shares of Vertex Pharmaceuticals gained about 6% Friday morning, after the pharmaceutical company won U.S. approval for the first new non-opioid painkiller in decades. …

yahoo.com

2%
OFF

Vertex Pharmaceuticals Stock Jumps After FDA Approval For New …

2 weeks from now

The approval was largely expected, but shares of Vertex jumped 5.2% early Friday. The FDA approved the drug to treat acute pain, meaning short-term pain from a procedure or injury.

msn.com

9%
OFF

Vertex Pharmaceuticals Stock Jumps As FDA Approves Non-opioid …

2 weeks from now

5 days ago · Other analysts, however, were more optimistic about Vertex’s long-term gains. Forbes extrapolated Vertex’s 9% rally in after-market hours on January 30 after the approval …

cphi-online.com

FAQs about Vertex Pharmaceuticals Shares Gain After FDA Approves Non … Coupon?

Why did Vertex Pharmaceuticals stock rise 8% in off-hours trading?

Shares of Vertex Pharmaceuticals rose 8% in off-hours trading after the pharmaceutical company won U.S. approval for the first new non-opioid painkiller in decades. The Food and Drug Administration approved Vertex's suzetrigine to treat moderate to severe acute pain. The drug is set to be sold under the brand name Journavx. ...

What will Vertex Pharmaceuticals' Q4 2024 results look like?

All eyes are on Vertex Pharmaceuticals’ upcoming Q4 2024 results, scheduled for February 11, after the stock’s recent surge. Analysts expect earnings per share (EPS) of $4 and revenue of $2.78 billion, representing a 10.3% year-over-year increase. ...

Will vertex use journavx as its brand name?

It will use Journavx as its brand name. Vertex CEO Reshma Kewalramani touted Journavx as the "first new class of pain medicine approved in more than 20 years," adding that the company has the "opportunity to change the paradigm of acute pain management and establish a new standard of care." ...

Is vertex a suzetrigine pain pill?

A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug Administration (FDA). The company’s "first-in-class" suzetrigine pain pill received the green light for treating moderate to severe acute pain in adults on Thursday, the federal agency said. ...

How much does vertex cost?

Vertex will charge $15.50 per pill, or $217 for a week’s prescription. Already a WSJ subscriber? Sign in ...

What does vertex's acquisition of Alpine Immune Sciences mean for nephropathy?

Complementing this, Vertex’s $4.6 billion acquisition of Alpine Immune Sciences positions it to target the kidney disease market with Povetacicept — a new drug targetting the $5 billion IgA nephropathy market, with Phase III trials commencing later this year. ...